Pancreatic Cancer Research

ResearcherPeking UniversityActive in the last 2 years

Lin Shen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8798-4756; OpenAlex author ID A5073838859. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper

Papers 7

  1. A phase 1b/2 study of first-line anti-PD-L1/ TGF-βRII fusion protein SHR-1701 combined with nab-paclitaxel and gemcitabine for advanced pancreatic ductal adeno… Last author DOI 10.1038/s41392-025-02530-2↗
  2. Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials. Last author DOI 10.1200/jco.23.02314↗
  3. CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer. Last author DOI 10.1186/s13045-023-01491-9↗
  4. Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer. Co-author DOI 10.1200/jco.22.02630↗
  5. Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2147/cmar.s263773↗
  6. [Pharmacotherapy for pancreatic cancer: Difficulties and prospects]. Last author DOI 10.3760/cma.j.issn.0253-3766.2017.09.014↗
  7. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Co-author DOI 10.1373/clinchem.2011.172767↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jun Zhou · 2 shared papers, 2020–2025 · strength 0.37
  2. Changsong Qi · 2 shared papers, 2023–2024 · strength 0.34
  3. Jun Zhou · 2 shared papers, 2023–2024 · strength 0.34
  4. Jun Zhang Zhang · 2 shared papers, 2023–2024 · strength 0.30
  5. Zhi-Hua Li · 1 shared paper, 2025 · strength 0.24
  6. Miaoyan Wei · 1 shared paper, 2025 · strength 0.24
  7. Ran Xue · 1 shared paper, 2025 · strength 0.24
  8. Xianjun Yu · 1 shared paper, 2025 · strength 0.24
  9. Yuhong Zhou · 1 shared paper, 2025 · strength 0.24
  10. Yuan Zong · 1 shared paper, 2020 · strength 0.13
  11. Chunyi Hao · 1 shared paper, 2023 · strength 0.13
  12. Tianshu Liu · 1 shared paper, 2023 · strength 0.13
  13. Ying Yuan · 1 shared paper, 2023 · strength 0.13
  14. Hongmei Zhang · 1 shared paper, 2023 · strength 0.13
  15. Lin Yang · 1 shared paper, 2023 · strength 0.13
  16. Jianming Xu · 1 shared paper, 2023 · strength 0.13
  17. Rui‐Hua Xu · 1 shared paper, 2023 · strength 0.13
  18. Qingshan Zheng · 1 shared paper, 2023 · strength 0.13
  19. Jin Li · 1 shared paper, 2023 · strength 0.13
  20. Shukui Qin · 1 shared paper, 2023 · strength 0.13
  21. Deliang Fu · 1 shared paper, 2023 · strength 0.13
  22. Zhenghang Wang · 1 shared paper, 2017 · strength 0.12
  23. Chen-Yu Zhang · 1 shared paper, 2012 · strength 0.03
  24. Zhao‐Shen Li · 1 shared paper, 2012 · strength 0.03
  25. Cheng Wang · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.